Tumor vasculature targeting through NGR peptide-based drugdelivery systems

Current Pharmaceutical Biotechnology

Volumn 12, Issue 8, 2011, Pages 1128-1134

  Corti, Angelo ^a   Curnis, Flavio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

v 3 integrin; Angiogenesis; Asparaginedeamidation; CD13; Isoaspartate; IsoDGR; NGR motif; NGR TNF; Peptide phage display library; Vascular targeting

Indexed keywords

ALPHA2A INTERFERON; ASPARAGINE; ASPARTIC ACID; CYAN FLUORESCENT PROTEIN; CYTOKINE; DOXORUBICIN; ENDOSTATIN; GAMMA INTERFERON; GLYCINE; MICROSOMAL AMINOPEPTIDASE; MOLECULAR SCAFFOLD; NANOPARTICLE; NUCLEIC ACID; PLASMID DNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMSTATIN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; DENDRITIC CELL; DNA DRUG COMPLEX; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; DRUG STABILITY; ENDOTHELIUM CELL; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOGENE C MYC; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR VASCULARIZATION; VIRUS PARTICLE;

ANGIOGENESIS INHIBITORS; ANIMALS; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; OLIGOPEPTIDES;

ANIMALIA;

EID: 79951822182     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111796117373     Document Type: Article

References (82)

1. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 2002, 29 (6 Suppl 16), 15-18.
2. Naumov, G. N.; Akslen, L. A.; Folkman, J. Role of angiogenesis inhuman tumor dormancy: animal models of the angiogenic switch. Cell Cycle, 2006, 5 (16), 1779-1787.
3. Folkman, J.; Shing, Y. Angiogenesis. J. Biol. Chem., 1992, 267(16), 10931-10934.
4. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment bytargeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279 (5349), 377-380.
5. Corti, A.; Curnis, F.; Arap, W.; Pasqualini, R., The neovasculaturehoming motif NGR: more than meets the eye. Blood, 2008, 112 (7),2628-2635.
6. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeuticproperties by targeted delivery to aminopeptidase N(CD13). Nat. Biotechnol., 2000, 18 (11), 1185-1190.
7. Colombo, G.; Curnis, F.; De Mori, G. M.; Gasparri, A.; Longoni, C.; Sacchi, A.; Longhi, R.; Corti, A. Structure-activity relationshipsof linear and cyclic peptides containing the NGR tumor-homingmotif. J. Biol. Chem., 2002, 277 (49), 47891-47897.
8. Curnis, F.; Arrigoni, G.; Sacchi, A.; Fischetti, L.; Arap, W.; Pasqualini, R.; Corti, A. Differential binding of drugs containingthe NGR motif to CD13 isoforms in tumor vessels, epithelia, andmyeloid cells. Cancer Res., 2002, 62 (3), 867-874.
9. Curnis, F.; Gasparri, A.; Sacchi, A.; Cattaneo, A.; Magni, F.; Corti, A. Targeted delivery of IFNgamma to tumor vessels uncouplesantitumor from counterregulatory mechanisms. Cancer Res., 2005,65 (7), 2906-2913.
10. Sacchi, A.; Gasparri, A.; Curnis, F.; Bellone, M.; Corti, A. Crucialrole for interferon gamma in the synergism between tumorvasculature-targeted tumor necrosis factor alpha (NGR-TNF) anddoxorubicin. Cancer Res., 2004, 64 (19), 7150-7155.
11. Crippa, L.; Gasparri, A.; Sacchi, A.; Ferrero, E.; Curnis, F.; Corti, A. Synergistic damage of tumor vessels with ultra low-doseendothelial-monocyte activating polypeptide-II and neovasculaturetargetedtumor necrosis factor-alpha. Cancer Res., 2008, 68 (4),1154-1161.
12. Pastorino, F.; Brignole, C.; Marimpietri, D.; Cilli, M.; Gambini, C.; Ribatti, D.; Longhi, R.; Allen, T. M.; Corti, A.; Ponzoni, M. Vascular damage and anti-angiogenic effects of tumor vesseltargetedliposomal chemotherapy. Cancer Res., 2003, 63 (21),7400-7409.
13. Pastorino, F.; Brignole, C.; Di Paolo, D.; Nico, B.; Pezzolo, A.; Marimpietri, D.; Pagnan, G.; Piccardi, F.; Cilli, M.; Longhi, R.; Ribatti, D.; Corti, A.; Allen, T. M.; Ponzoni, M. Targetingliposomal chemotherapy via both tumor cell-specific and tumorvasculature-specific ligands potentiates therapeutic efficacy. Cancer Res., 2006, 66 (20), 10073-10082.
14. Ellerby, H. M.; Arap, W.; Ellerby, L. M.; Kain, R.; Andrusiak, R.; Rio, G. D.; Krajewski, S.; Lombardo, C. R.; Rao, R.; Ruoslahti, E.; Bredesen, D. E.; Pasqualini, R. Anti-cancer activity of targeted proapoptoticpeptides. Nat. Med., 1999, 5 (9), 1032-1038.
15. Meng, J.; Yan, Z.; Wu, J.; Li, L.; Xue, X.; Li, M.; Li, W.; Hao, Q.; Wan, Y.; Qin, X.; Zhang, C.; You, Y.; Han, W.; Zhang, Y. Highyieldexpression, purification and characterization of tumortargetedIFN-alpha2a. Cytotherapy, 2007, 9 (1), 60-68.
16. Meng, J.; Ma, N.; Yan, Z.; Han, W.; Zhang, Y. NGR enhanced theanti-angiogenic activity of tum-5. J. Biochem. (Tokyo), 2006, 140(2), 299-304.
17. von Wallbrunn, A.; Waldeck, J.; Holtke, C.; Zuhlsdorf, M.; Mesters, R.; Heindel, W.; Schafers, M.; Bremer, C., In vivo opticalimaging of CD13/APN-expression in tumor xenografts. J. Biomed.Opt., 2008, 13 (1), 011007.
18. Yokoyama, Y.; Ramakrishnan, S. Addition of an aminopeptidaseN-binding sequence to human endostatin improves inhibition ofovarian carcinoma growth. Cancer, 2005, 104 (2), 321-331.
19. Buehler, A.; van Zandvoort, M. A.; Stelt, B. J.; Hackeng, T. M.; Schrans-Stassen, B. H.; Bennaghmouch, A.; Hofstra, L.; Cleutjens, J. P.; Duijvestijn, A.; Smeets, M. B.; de Kleijn, D. P.; Post, M. J.; de Muinck, E. D. cNGR: a novel homing sequence for CD13/APNtargeted molecular imaging of murine cardiac angiogenesis in vivo.Arterioscler. Thromb. Vasc. Biol., 2006, 26 (12), 2681-2687.
20. Zarovni, N.; Monaco, L.; Corti, A. Inhibition of tumor growth byintramuscular injection of cDNA encoding tumor necrosis factoralpha coupled to NGR and RGD tumor-homing peptides. Hum.Gene Ther., 2004, 15 (4), 373-382.
21. Grifman, M.; Trepel, M.; Speece, P.; Gilbert, L. B.; Arap, W.; Pasqualini, R.; Weitzman, M. D. Incorporation of tumor-targetingpeptides into recombinant adeno-associated virus capsids. Mol.Ther., 2001, 3 (6), 964-975.
22. Liu, L.; Anderson, W. F.; Beart, R. W.; Gordon, E. M.; Hall, F. L. Incorporation of tumor vasculature targeting motifs into moloneymurine leukemia virus env escort proteins enhances retrovirusbinding and transduction of human endothelial cells. J. Virol.,2000, 74 (11), 5320-5328.
23. Moffatt, S.; Wiehle, S.; Cristiano, R. J. Tumor-specific genedelivery mediated by a novel peptide-polyethylenimine-DNApolyplex targeting aminopeptidase N/CD13. Hum. Gene Ther.,2005, 16 (1), 57-67.
24. Moffatt, S.; Cristiano, R. J. Uptake characteristics of NGR-coupledstealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGAtri-block copolymer for targeted delivery to human monocytederiveddendritic cells. Int. J. Pharm., 2006, 321 (1-2), 143-154.
25. Holle, L.; Song, W.; Hicks, L.; Holle, E.; Holmes, L.; Wei, Y.; Li, J.; Wagner, T.; Yu, X. In vitro targeted killing of humanendothelial cells by co-incubation of human serum and NGRpeptide conjugated human albumin protein bearing alpha (1-3)galactose epitopes. Oncol. Rep., 2004, 11 (3), 613-616.
26. Zhang, Z.; Harada, H.; Tanabe, K.; Hatta, H.; Hiraoka, M.; Nishimoto, S. Aminopeptidase N/CD13 targeting fluorescentprobes: synthesis and application to tumor cell imaging. Peptides,2005, 26 (11), 2182-2187.
27. Dirksen, A.; Langereis, S.; de Waal, B. F.; van Genderen, M. H.; Meijer, E. W.; de Lussanet, Q. G.; Hackeng, T. M. Design andsynthesis of a bimodal target-specific contrast agent forangiogenesis. Org. Lett., 2004, 6 (26), 4857-4860.
28. Oostendorp, M.; Douma, K.; Hackeng, T. M.; Dirksen, A.; Post, M.J.; van Zandvoort, M. A.; Backes, W. H. Quantitative molecularmagnetic resonance imaging of tumor angiogenesis using cNGRlabeledparamagnetic quantum dots. Cancer Res., 2008, 68 (18),7676-7683.
29. Majhen, D.; Gabrilovac, J.; Eloit, M.; Richardson, J.; Ambriovic-Ristov, A. Disulfide bond formation in NGR fiber-modifiedadenovirus is essential for retargeting to aminopeptidase N. Biochem. Biophys. Res. Commun., 2006, 348 (1), 278-287.
30. Bieker, R.; Kessler, T.; Schwoppe, C.; Padro, T.; Persigehl, T.; Bremer, C.; Dreischaluck, J.; Kolkmeyer, A.; Heindel, W.; Mesters, R. M.; Berdel, W. E. Infarction of tumor vessels by NGRpeptide-directed targeting of tissue factor: experimental results andfirst-in-man experience. Blood, 2009, 113 (20), 5019-5027.
31. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R. A.; Shapiro, L. H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homingpeptides and a target for inhibiting angiogenesis. Cancer Res.,2000, 60 (3), 722-727.
32. Chen, Y.; Wu, J. J.; Huang, L. Nanoparticles targeted with NGRmotif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol. Ther., 2010, in press.
33. Curnis, F.; Sacchi, A.; Gasparri, A.; Longhi, R.; Bachi, A.; Doglioni, C.; Bordignon, C.; Traversari, C.; Rizzardi, G.; Corti, A. Isoaspartate-glycine-arginine: A new tumor vasculature-targetingmotif. Cancer Res., 2008, 68 (17), 7073-7082.
34. Jullienne, B.; Vigant, F.; Muth, E.; Chaligne, R.; Bouquet, C.; Giraudier, S.; Perricaudet, M.; Benihoud, K. Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther., 2009, 16 (12), 1405-1415.
35. Garde, S. V.; Forte, A. J.; Ge, M.; Lepekhin, E. A.; Panchal, C. J.; Rabbani, S. A.; Wu, J. J. Binding and internalization of NGRpeptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs, 2007,18 (10), 1189-1200.
36. Wang, X.; Wang, Y.; Chen, X.; Wang, J.; Zhang, X.; Zhang, Q. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J. Control. Release,2009, 139 (1), 56-62.
37. Negussie, A. H.; Miller, J. L.; Reddy, G.; Drake, S. K.; Wood, B.J.; Dreher, M. R. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J. Control. Release,2010, in press.
38. Fransen, L.; Muller, R.; Marmenout, A.; Tavernier, J.; Van derHeyden, J.; Kawashima, E.; Chollet, A.; Tizard, R.; VanHeuverswyn, H.; Van Vliet, A. et al., Molecular cloning of mousetumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res., 1985, 13 (12), 4417-4429.
39. Bhagwat, S. V.; Lahdenranta, J.; Giordano, R.; Arap, W.; Pasqualini, R.; Shapiro, L. H. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 2001, 97 (3), 652-659.
40. Menrad, A.; Speicher, D.; Wacker, J.; Herlyn, M. Biochemical andfunctional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res., 1993, 53 (6), 1450-1455.
41. Saiki, I.; Fujii, H.; Yoneda, J.; Abe, F.; Nakajima, M.; Tsuruo, T.; Azuma, I. Role of aminopeptidase N (CD13) in tumor-cell invasionand extracellular matrix degradation. Int. J. Cancer., 1993, 54 (1),137-143.
42. Rangel, R.; Sun, Y.; Guzman-Rojas, L.; Ozawa, M. G.; Sun, J.; Giordano, R. J.; Van Pelt, C. S.; Tinkey, P. T.; Behringer, R. R.; Sidman, R. L.; Arap, W.; Pasqualini, R. Impaired angiogenesis inaminopeptidase N-null mice. Proc. Natl. Acad Sci. U S A., 2007,104 (11), 4588-4593.
43. Fukasawa, K.; Fujii, H.; Saitoh, Y.; Koizumi, K.; Aozuka, Y.; Sekine, K.; Yamada, M.; Saiki, I.; Nishikawa, K. AminopeptidaseN (APN/CD13) is selectively expressed in vascular endothelialcells and plays multiple roles in angiogenesis. Cancer Lett., 2006,243 (1), 135-143.
44. Hashida, H.; Takabayashi, A.; Kanai, M.; Adachi, M.; Kondo, K.; Kohno, N.; Yamaoka, Y.; Miyake, M. Aminopeptidase N isinvolved in cell motility and angiogenesis: its clinical significancein human colon cancer. Gastroenterology, 2002, 122 (2), 376-386.
45. Look, A. T.; Ashmun, R. A.; Shapiro, L. H.; Peiper, S. C. Humanmyeloid plasma membrane glycoprotein CD13 (gp150) is identicalto aminopeptidase N. J. Clin. Invest., 1989, 83 (4), 1299-1307.
46. Look, A. T.; Peiper, S. C.; Rebentisch, M. B.; Ashmun, R. A.; Roussel, M. F.; Rettenmier, C. W.; Sherr, C. J. Transfer andexpression of the gene encoding a human myeloid membraneantigen (gp150). J. Clin. Invest., 1985, 75 (2), 569-579.
47. Razak, K.; Newland, A. C., The significance of aminopeptidasesand haematopoietic cell differentiation. Blood Rev., 1992, 6 (4),243-250.
48. O'Connell, P. J.; Gerkis, V.; d'Apice, A. J. Variable Oglycosylationof CD13 (aminopeptidase N). J. Biol. Chem., 1991,266 (7), 4593-4597.
49. Santos, A. N.; Langner, J.; Herrmann, M.; Riemann, D. Aminopeptidase N/CD13 is directly linked to signal transductionpathways in monocytes. Cell Immunol., 2000, 201 (1), 22-32.
50. Riemann, D.; Kehlen, A.; Langner, J. CD13 - not just a marker inleukemia typing. Immunol. Today, 1999, 20 (2), 83-88.
51. Matsas, R.; Stephenson, S. L.; Hryszko, J.; Kenny, A. J.; Turner, A.J., The metabolism of neuropeptides. Phase separation of synapticmembrane preparations with Triton X-114 reveals the presence ofaminopeptidase N. Biochem. J., 1985, 231 (2), 445-449.
52. Hoffmann, T.; Faust, J.; Neubert, K.; Ansorge, S. Dipeptidylpeptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzedhydrolysis of cytokines and peptides with N-terminal cytokinesequences. FEBS Letters, 1993, 336 (1), 61-64.
53. Oostendorp, M.; Douma, K.; Wagenaar, A.; Slenter, J. M.; Hackeng, T. M.; van Zandvoort, M. A.; Post, M. J.; Backes, W. H. Molecular magnetic resonance imaging of myocardial angiogenesisafter acute myocardial infarction. Circulation, 2010, 121 (6), 775-783.
54. Lahdenranta, J.; Sidman, R. L.; Pasqualini, R.; Arap, W. Treatmentof hypoxia-induced retinopathy with targeted proapoptoticpeptidomimetic in a mouse model of disease. FASEB J., 2007, 21(12), 3272-3278.
55. Taylor, A. Aminopeptidases: structure and function. FASEB J.,1993, 7 (2), 290-298.
56. Shipp, M. A.; Look, A. T. Hematopoietic differentiation antigensthat are membrane-associated enzymes: cutting is the key. Blood,1993, 82 (4), 1052-1070.
57. Dixon, J.; Kaklamanis, L.; Turley, H.; Hickson, I. D.; Leek, R. D.; Harris, A. L.; Gatter, K. C. Expression of aminopeptidase-n (CD13) in normal tissues and malignant neoplasms of epithelial andlymphoid origin. J. Clin. Pathol., 1994, 47 (1), 43-47.
58. Chen, H.; Kinzer, C. A.; Paul, W. E. p161, a murine membraneprotein expressed on mast cells and some macrophages, is mouseCD13/aminopeptidase N. J. Immunol., 1996, 157 (6), 2593-2600.
59. Drexler, H. G. Classification of acute myeloid leukemias--acomparison of FAB and immunophenotyping. Leukemia, 1987, 1(10), 697-705.
60. Pastorino, F.; Di Paolo, D.; Piccardi, F.; Nico, B.; Ribatti, D.; Daga, A.; Baio, G.; Neumaier, C. E.; Brignole, C.; Loi, M.; Marimpietri, D.; Pagnan, G.; Cilli, M.; Lepekhin, E. A.; Garde, S.V.; Longhi, R.; Corti, A.; Allen, T. M.; Wu, J. J.; Ponzoni, M.Enhanced antitumor efficacy of clinical-grade vasculature-targetedliposomal doxorubicin. Clin. Cancer. Res., 2008, 14 (22), 7320-7329.
61. Mukhopadhyay, S.; Barnes, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Conjugated platinum(IV)-peptidecomplexes for targeting angiogenic tumor vasculature. Bioconjug.Chem., 2008, 19 (1), 39-49.
62. Ndinguri, M. W.; Solipuram, R.; Gambrell, R. P.; Aggarwal, S.; Hammer, R. P. Peptide targeting of platinum anti-cancer drugs. Bioconjug. Chem., 2009, in press.
63. Zhang, Z.; Hatta, H.; Tanabe, K.; Nishimoto, S. A new class of 5-fluoro-2'-deoxyuridine prodrugs conjugated with a tumor-homingcyclic peptide CNGRC by ester linkers: synthesis, reactivity, andtumor-cell-selective cytotoxicity. Pharm. Res., 2005, 22 (3), 381-389.
64. Zhang, Z.; Hatta, H.; Ito, T.; Nishimoto, S. Synthesis andphotochemical properties of photoactivated antitumor prodrugsreleasing 5-fluorouracil. Org. Biomol. Chem., 2005, 3 (4), 592-596.
65. Corti, A.; Ponzoni, M. Tumor vascular targeting with tumornecrosis factor alpha and chemotherapeutic drugs. Ann. N. Y. Acad.Sci., 2004, 1028, 104-112.
66. Sacchi, A.; Gasparri, A.; Gallo-Stampino, C.; Toma, S.; Curnis, F.; Corti, A. Synergistic antitumor activity of cisplatin, paclitaxel, andgemcitabine with tumor vasculature-targeted tumor necrosis factoralpha. Clin. Cancer. Res., 2006, 12 (1), 175-182.
67. Curnis, F.; Sacchi, A.; Corti, A. Improving chemotherapeutic drugpenetration in tumors by vascular targeting and barrier alteration. J.Clin. Invest., 2002, 110 (4), 475-482.
68. Gregorc, V.; Santoro, A.; Bennicelli, E.; Punt, C. J.; Citterio, G.; Timmer-Bonte, J. N.; Caligaris Cappio, F.; Lambiase, A.; Bordignon, C.; van Herpen, C. M. Phase Ib study of NGR-hTNF, aselective vascular targeting agent, administered at low doses incombination with doxorubicin to patients with advanced solidtumours. Br. J. Cancer., 2009, 101 (2), 219-224.
69. van Laarhoven, H. W.; Fiedler, W.; Desar, I. M.; van Asten, J. J.; Marreaud, S.; Lacombe, D.; Govaerts, A. S.; Bogaerts, J.; Lasch, P.; Timmer-Bonte, J. N.; Lambiase, A.; Bordignon, C.; Punt, C. J.; Heerschap, A.; van Herpen, C. M. Phase I clinical and magneticresonance imaging study of the vascular agent NGR-hTNF inpatients with advanced cancers (European Organization forResearch and Treatment of Cancer Study 16041). Clin. Cancer.Res., 2010, 16 (4), 1315-1323.
70. Gleave, M. E.; Elhilali, M.; Fradet, Y.; Davis, I.; Venner, P.; Saad, F.; Klotz, L. H.; Moore, M. J.; Paton, V.; Bajamonde, A. Interferongamma-1b compared with placebo in metastatic renal-cellcarcinoma. Canadian Urologic Oncology Group. New Engl. J.Med., 1998, 338 (18), 1265-1271.
71. Meng, J.; Yan, Z.; Wu, Y.; Gao, M.; Li, W.; Gao, F.; Wang, H.; Han, W.; Zhang, Y. Preclinical safety evaluation of IFNalpha2a-NGR. Regul. Toxicol. Pharmacol., 2008, 50 (3), 294-302.
72. Yokoyama, Y.; Ramakrishnan, S. Improved biological activity of amutant endostatin containing a single amino-acid substitution. Br.J. Cancer, 2004, 90 (8), 1627-1635.
73. Mizuguchi, H.; Koizumi, N.; Hosono, T.; Utoguchi, N.; Watanabe, Y.; Kay, M. A.; Hayakawa, T. A simplified system for constructingrecombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther., 2001, 8 (9), 730-735.
74. Li, H.; Wang, J.; Zhou, T.; Zhang, Y.; Zhang, Z. An investigationof the effects of nanosize delivery system for antisense oligonucleotideon esophageal squamous cancer cells. Cancer. Biol. Ther.,2008, 7 (11).
75. Koivunen, E.; Gay, D. A.; Ruoslahti, E. Selection of peptidesbinding to the alpha 5 beta 1 integrin from phage display library. J.Biol. Chem., 1993, 268 (27), 20205-20210.
76. Asokan, A.; Hamra, J. B.; Govindasamy, L.; Agbandje-McKenna, M.; Samulski, R. J. Adeno-associated virus type 2 contains anintegrin alpha5beta1 binding domain essential for viral cell entry. J.Virol., 2006, 80 (18), 8961-8969.
77. Curnis, F.; Cattaneo, A.; Longhi, R.; Sacchi, A.; Gasparri, A. M.; Pastorino, F.; Di Matteo, P.; Traversari, C.; Bachi, A.; Ponzoni, M.; Rizzardi, G. P.; Corti, A. Critical role of flanking residues in NGRto-isoDGR transition and CD13/Integrin receptor switching. J.Biol. Chem., 2010, 285 (12), 9114-9123.
78. Curnis, F.; Longhi, R.; Crippa, L.; Cattaneo, A.; Dondossola, E.; Bachi, A.; Corti, A. Spontaneous formation of L-isoaspartate andgain of function in fibronectin. J. Biol. Chem., 2006, 281 (47),36466-36476.
79. Lura, R.; Schirch, V. Role of peptide conformation in the rate andmechanism of deamidation of asparaginyl residues. Biochemistry,1988, 27 (20), 7671-7677.
80. Dehart, M. P.; Anderson, B. D. The role of the cyclic imide inalternate degradation pathways for asparagine-containing peptidesand proteins. J. Pharm. Sci., 2007, 96 (10), 2667-2685.
81. Spitaleri, A.; Mari, S.; Curnis, F.; Traversari, C.; Longhi, R.; Bordignon, C.; Corti, A.; Rizzardi, G. P.; Musco, G. Structuralbasis for the interaction of isoDGR with the RGD-binding site ofalphavbeta3 integrin. J. Biol. Chem., 2008, 283 (28), 19757-19768.
82. Di Matteo, P.; Curnis, F.; Longhi, R.; Colombo, G.; Sacchi, A.; Crippa, L.; Protti, M. P.; Ponzoni, M.; Toma, S.; Corti, A. Immunogenic and structural properties of the Asn-Gly-Arg (NGR)tumor neovasculature-homing motif. Mol. Immunol., 2006, 43 (10),1509-1518.